Bibliography
- Jemal A, Siegel R, Xu J, Cancer statistics, 2010. CA Cancer J Clin 2010;12:277-300
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717
- Muller V, Witzel I, Stickeler E. Immunological approaches in the treatment of metastasized breast cancer. Breast Care 2009;4(6):359-66
- Govindan S, Goldenberg D. New antibody conjugates in cancer therapy. Sci World J 2010;10:2070-89
- Investigator's brochure for CR011-vcMMAE. CuraGen Corp., version 2, March 18, 2008
- Tse K, Jeffers M, Pollack V, CRO11, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Caner Res 2006;12(4):1373-82
- Rich J, Shi Q, Hjelmeland M, Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. J Biol Chem 2003;278(18):15951-7
- Onaga M, Ido A, Hasuike S, Osteoactivin expressed during cirrhosis development in rats fed a choline-deficient, L-amino acid-defined diet, accelerates motility of hepatoma cells. J Hepatol 2003;39(5):779-85
- Rose AA, Pepin F, Russo C, Osteoactivin promotes breast cancer metastasis to bone. Mol Cancer Res 2007;5(10):1001-14
- Rose A, Grosset A, Dong Z, Glycoprotein Nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clin Cancer Res 2010;16:2147-56
- Pollack V, Alvarez E, Tse E, Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011- vcMMAE) targeting GPNMB. Cancer Chemother Pharmacol 2007;60(3):423-35
- Rose A, Dong Z, MacDonald P, GPNMB is Novel Pro-Angiogenic Factor and Therapeutic Target in Breast Cancer. Poster Presented at MISAM (Montreal International Symposium on Angiogenesis and Metastasis); June 2009
- Kovtun Y, Audette C, Ye Y, Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 2006;66(6):3214-21
- Burris H, Saleh M, Bendell J, A Phase I/II Study of CR011-vcMMAE (CDX-011), an Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Breast Cancer [abstract 6096]. 2009 San Antonio Breast Cancer Symposium (SABCS)
- Hwu P, Sznol M, Pavlick A, A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate (ADC) targeting glycoprotein NMB (GPNMB) in patients (pts) with advanced melanoma. J Clin Oncol 2009;27(15 Suppl):abstract 9032
- Saleh M, Bendell J, Rose R, Correlation of GPNMB expression with outcome in breast cancer (BC) patients treated with antibody-drug conjugate (ADC), CDX-011 (CR011-vMMAE). J Clin Oncol 2010;28(15 Suppl):abstract 1095
- Barry D, Cronin K, Plevritis S, Effect of screening and adjuvant therapy on mortality from breast cancer. NEJM 2005;353:1784-92
- Alley S, Okeley N, Senter P. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 2010;14(4):529-37